BerGenBio ASA: Results for the First Quarter 2017
Bergen, Norway, 23 May 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2017. A presentation of the results by the company’s senior management team will take place today at 10:00a.m. CET in Oslo - details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “During Q1 2017, BerGenBio has established a strong foundation from which to advance our development strategy for BGB324, a first-in-class, selective, oral Axl inhibitor,